Author Archives: admin

BIFR Update


BIFR referred Gujarat Themis Biosyn Ltd., has significantly surpassed the profitability projections as per scheme of Rehabilitation. Net Profit for the year ended 31st March, 2014 was Rs. 452.60 lakhs as against net profit of Rs. 106.98 lakhs for the year ended 31st March, 2013. The negative Net worth of the Company has come down to Rs.534 lakhs as on 31st March 2014 as against Rs. 987 lakhs on 31st March 2013. EPS for the current year stood at Rs. […]

BIFR Update


In line with order passed by BIFR on 20th November, 2013 and 2nd January 2014, SEBI passed an order dated 28th March, 2014 allowing the Company to extend the time to comply with minimum public shareholding on or before 19th August, 2014. Also the Company allowed to increase in equity shares from 14,71,250 to 18,96,500 of Rs. 5/- each fully paid up, through public offer or private offer or through any other mode as well as at price as permitted […]

Results


Gujarat Themis Biosyn Ltd. has recorded turnover of Rs. 2294.10 Lakhs for the current nine months ended 31st December, 2013, as compared to Rs.2104.08 Lakhs during the corresponding period ended 31st December, 2012. The Company recorded Net Profit of Rs.317.64 Lakhs for the current nine months ended 31st December, 2013 as compared to Rs.111.56 Lakhs during the corresponding period ended 31st December, 2012. The profit generation recorded exceeds the BIFR approved Scheme for the period under reference.

BIFR Update


Gujarat Themis Biosyn Limited (GTBL) for which Rehabilitation Scheme was sanctioned by Board for Industrial Reconstruction (BIFR) on 12.01.2012. The Company under the umbrella of Themis Medicare’s management has started yielding positive results. The Company has a long term contract with a Pharma major to manufacture Active Pharmaceutical Ingredient (API). GTBL started positive profits from September 2012 quarter and thereafter the profits have been consistently on rise. Whereas in the quarter ended June 2013 profit of Rs. 84.78 lakhs was […]

Started manufacture of Rifamycin S an intermediate for Rifampicin, currently plant is running at full capacity with this product.


Started manufacture of Rifamycin S an intermediate for Rifampicin, currently plant is running at full capacity with this product. This post is part of the thread: Timeline – an ongoing story on this site. View the thread timeline for more context on this post.

Started manufacture of Lovastatin.


Started manufacture of Lovastatin. This post is part of the thread: Timeline – an ongoing story on this site. View the thread timeline for more context on this post.

GTBL developed 3 Formyl Rifamycin SV (3FRSV) and Rifampicin IP.


GTBL developed 3 Formyl Rifamycin SV (3FRSV) and Rifampicin IP. This post is part of the thread: Timeline – an ongoing story on this site. View the thread timeline for more context on this post.

Entered into a Joint venture agreement with Yuhan Corporation of South Korea to manufacture Rifampicin.


Entered into a Joint venture agreement with Yuhan Corporation of South Korea to manufacture Rifampicin. This post is part of the thread: Timeline – an ongoing story on this site. View the thread timeline for more context on this post.

Establishment of Gujarat Themis Biosyn Ltd in Fermentation business for manufacture of Erythromycin.


Establishment of Gujarat Themis Biosyn  Ltd in  Fermentation business for manufacture of Erythromycin. This post is part of the thread: Timeline – an ongoing story on this site. View the thread timeline for more context on this post.